EARLY DETECTION AND MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH IPILIMUMAB: HOW THE RESEARCH NURSE PLAYS A VITAL ROLE

2.50
Hdl Handle:
http://hdl.handle.net/10755/164722
Category:
Abstract
Type:
Presentation
Title:
EARLY DETECTION AND MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH IPILIMUMAB: HOW THE RESEARCH NURSE PLAYS A VITAL ROLE
Author(s):
Levy, Catherine; Allen, Tamika
Author Details:
Catherine Levy, MS, BSN, RN, Research Nurse Specialist, National Institutes of Health, Bethesda, Maryland, USA, email: catherinelevy@nih.gov; Tamika Allen, RN, BSN
Abstract:
Ipilimumab is a monoclonal antibody currently being used in clinical trials in a variety of diseases including melanoma, renal cell carcinoma, and adenocarcinoma of the pancreas. As Ipilimumab begins the fast track process for FDA approval, it is essential that oncology nurses understand the importance of early detection and management of potential adverse events. The primary action of Ipilimumab is to inhibit the CTLA4 molecule found on the surface of T cells and potentially enhances immune responses against cancer. However, Ipilimumab can result in autoimmune events such as colitis, hypophysitis, uveitis, dermatitis, hepatitis, and/or nephritis. Autoimmune events correlate with a higher rate of tumor regression. The research nurse plays an important role in the assessment and reporting of adverse events. Nursing responsibilities include providing comprehensive patient education, collection and analysis of patient symptoms, and monitoring laboratory values. Constant surveillance of adverse events facilitates prompt treatment to prevent long term or potentially fatal complications. The research nurseÆs role in educating study subjects on potential adverse events is part of the informed consent process. This process is ongoing as study participants remain enrolled on the clinical trial. Study subjects are provided with a Symptom Management Log to document any new symptoms. Examples of symptoms from Ipilimumab include diarrhea, abdominal cramping, fatigue, headaches, arthralgias, any visual changes, and any skin changes such as rash, itching, or discoloration. These symptoms appear anywhere from one week to a few months after receiving therapy. Each situation is evaluated individually and may warrant further work-up. Pending evaluation, steroid therapy may or may not be initiated. Steroids are not utilized as a front line therapy in mild forms of autoimmune events as they may inhibit immune response, however steroids may be indicated for severe autoimmune events such colitis or hypophysitis. As more clinical trials use Ipilimumab, unknown autoimmune events may surface. It is imperative that the research nurse maintains ongoing communication and close surveillance with participants who receive Ipilimumab.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleEARLY DETECTION AND MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH IPILIMUMAB: HOW THE RESEARCH NURSE PLAYS A VITAL ROLEen_GB
dc.contributor.authorLevy, Catherineen_US
dc.contributor.authorAllen, Tamikaen_US
dc.author.detailsCatherine Levy, MS, BSN, RN, Research Nurse Specialist, National Institutes of Health, Bethesda, Maryland, USA, email: catherinelevy@nih.gov; Tamika Allen, RN, BSNen_US
dc.identifier.urihttp://hdl.handle.net/10755/164722-
dc.description.abstractIpilimumab is a monoclonal antibody currently being used in clinical trials in a variety of diseases including melanoma, renal cell carcinoma, and adenocarcinoma of the pancreas. As Ipilimumab begins the fast track process for FDA approval, it is essential that oncology nurses understand the importance of early detection and management of potential adverse events. The primary action of Ipilimumab is to inhibit the CTLA4 molecule found on the surface of T cells and potentially enhances immune responses against cancer. However, Ipilimumab can result in autoimmune events such as colitis, hypophysitis, uveitis, dermatitis, hepatitis, and/or nephritis. Autoimmune events correlate with a higher rate of tumor regression. The research nurse plays an important role in the assessment and reporting of adverse events. Nursing responsibilities include providing comprehensive patient education, collection and analysis of patient symptoms, and monitoring laboratory values. Constant surveillance of adverse events facilitates prompt treatment to prevent long term or potentially fatal complications. The research nurseÆs role in educating study subjects on potential adverse events is part of the informed consent process. This process is ongoing as study participants remain enrolled on the clinical trial. Study subjects are provided with a Symptom Management Log to document any new symptoms. Examples of symptoms from Ipilimumab include diarrhea, abdominal cramping, fatigue, headaches, arthralgias, any visual changes, and any skin changes such as rash, itching, or discoloration. These symptoms appear anywhere from one week to a few months after receiving therapy. Each situation is evaluated individually and may warrant further work-up. Pending evaluation, steroid therapy may or may not be initiated. Steroids are not utilized as a front line therapy in mild forms of autoimmune events as they may inhibit immune response, however steroids may be indicated for severe autoimmune events such colitis or hypophysitis. As more clinical trials use Ipilimumab, unknown autoimmune events may surface. It is imperative that the research nurse maintains ongoing communication and close surveillance with participants who receive Ipilimumab.en_GB
dc.date.available2011-10-27T12:05:47Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:05:47Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.